ArticleMedicine2018
Impaired retinal pigment epithelium in paclitaxel-induced macular edema: A case report.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Carbonic anhydrase inhibitor alleviates retinal barrier toxicity in paclitaxel-induced retinopathy and macular edema by inhibiting CAXIV.International ophthalmology · 2024Article
- Cystoid macular oedema without leakage in fluorescein angiography: a literature review.Eye (London, England) · 2023Review
- Paclitaxel and Urolithin A Prevent Histamine-Induced Neurovascular Breakdown Alike, in anACS chemical neuroscience · 2022Article
- The effect of docetaxel on retinal pigment epithelial cells.Toxicology reports · 2022Article
- Case of cystoid macular edema induced by systemic administration of paclitaxel: evaluations with electroretinograms.Documenta ophthalmologica. Advances in ophthalmology · 2021Article
- Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports.Journal of medical case reports · 2021Article
- Unilateral cystoid macular edema and bilateral subfoveal hyperreflectivity following docetaxel chemotherapy: A case report.American journal of ophthalmology case reports · 2020Article
- Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy.American journal of ophthalmology case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCystoid macular edema (CME) is a rare complication of the paclitaxel. However, the pathophysiology was unknown. PATIENT CONCERNS: A 60-year-old female presented with bilateral blurred vision due to cystoid macular edema after taking 12-course paclitaxel for her breast cancer. Optical coherence tomography (OCT), fluorescein angiography (FAG), indocyanine green angiography (ICGA), electroretinogram (ERG) and electrooculogram (EOG) were performed. DIAGNOSES: Paclitaxel-induced macular edema.
interventionsPaclitaxel was discontinued and supportive treatment with pentoxifylline was given. OUTCOMES: The OCT showed bilateral cystoid macular edema. Impaired filling of choriocapillaries was noted on the ICGA; while EOG revealed decreased Arden ratio. The visual acuity, cystoid macular edema and decreased Arden ratio improved slowly over six months. LESSONS: Paclitaxel rarely causes cystoid macular edema. The damage of choriocapillaries and retinal pigment epithelium might be the underlying cause. Immediate discontinuation of the drug helps visual recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.